Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK)

Next Previous
X
Search
Trial Profile

A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceritinib (Primary)
  • Indications Anaplastic large cell lymphoma; Cancer; Glioma; Muscle tissue neoplasms; Neuroblastoma; Rhabdomyosarcoma; Sarcoma; Thyroid cancer
  • Focus Adverse reactions
  • Acronyms ASCEND-1
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 01 Jan 2022 Results of exploratory analysis of genetic determinants of response to ceritinib using tumor biopsies from anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small-cell lung cancer (NSCLC) patients, published in the Lung Cancer.
    • 12 Nov 2021 Results published in the Lancet Oncology
    • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top